Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Verdezyne Signs Distribution Agreement With Aceto Corporation

Verdezyne
Posted on: 05 Oct 16

PR Newswire

CARLSBAD, Calif. and PORT WASHINGTON, N.Y., Oct. 5, 2016

CARLSBAD, Calif. and PORT WASHINGTON, N.Y., Oct. 5, 2016 /PRNewswire/ -- Verdezyne Inc., a synthetic biology company producing biobased chemicals, and Aceto Corporation (ACET), the leader in the marketing, sales and distribution of specialty chemicals in the U.S., announced an agreement for sales and distribution of Verdezyne's BIOLON® DDDA (biobased dodecanedioic acid). BIOLON DDDA will be produced by Verdezyne and will be distributed in the United States of America by Aceto. 

Verdezyne's BIOLON DDDA is produced more sustainably than traditional petroleum-derived intermediate chemicals and will be used to make a variety of end-user products including automotive parts, coatings, cosmetics, and fragrances.

"The market is interested in high-quality renewable chemicals such as our BIOLON, which can be used in the production of high-performance nylon 6,12, molding resins, lubricants, adhesives and powder coatings," said E. William Radany, Ph.D., president and CEO of Verdezyne. "We are excited to bring BIOLON to the U.S. market with Aceto, a highly respected distributor of specialty chemicals. We are certain that through this partnership we will be able to continue to provide excellent customer service and high-quality products to the market."  

"Aceto is very excited to add BIOLON to our product offering of polymer building blocks," commented Keith Wilkinson, vice president, specialty chemicals Aceto. "We are also excited to add a biobased product to our portfolio that can be offered at competitive prices."

About Verdezyne
Verdezyne is a synthetic biology company offering biobased chemicals developed using proprietary metabolic pathway engineering tools. The company's first product, BIOLON® DDDA, earned the USDA Certified Biobased Product label, and is available worldwide. Current investors in Verdezyne include BP Ventures, DSM Venturing B.V., OVP Venture Partners, Monitor Ventures, and Sime Darby. For more information, visit www.verdezyne.com or connect with the company on Twitter, LinkedIn or Facebook.

About Aceto Corporation
ACETO Corporation (NASDAQ: ACET), incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).

For samples, orders or more information about Verdezyne's BIOLON, please contact:

Keith Wilkinson
kwilkinson@aceto.com

Verdezyne Media Contacts:

Paula Page
paula@paulapagepr.com
650-279-3881

Jenna Ngian
Vice President, Global Sales and Supply Chain
JNgian@Verdezyne.com  
760-707-5288 

Aceto Corporation Media Contact:

Jody Burfening
jburfening@lhai.com 
212-838-3777

Logo - http://photos.prnewswire.com/prnh/20161003/414701LOGO 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/verdezyne-signs-distribution-agreement-with-aceto-corporation-300339416.html

SOURCE Verdezyne

PR Newswire
www.prnewswire.com

Last updated on: 05/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.